Revised forecast
Fiscal year ending March 2026 · Full yearNo earnings forecast for the fiscal year ending March 2027 is provided because the company's shares are scheduled to be delisted following the tender offer by the tender offeror and the subsequent series of procedures. The reported results for the fiscal year ended March 2026 cite firm orders for blood pressure monitor cuffs, increased production volumes, a weaker yen against the U.S. dollar, and strong car-seat production at the Vietnam plant, among other factors.
Tender offer-related expenses ¥128.500 million, impairment loss ¥32.037 million, loss on disposal of fixed assets ¥0.995 million, total extraordinary losses ¥161.533 million
| Item | Details |
|---|---|
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2025: net sales ¥9,567 million, operating income ¥1,953 million, ordinary income ¥2,054 million, net income attributable to owners of the parent ¥1,560 million, earnings per share ¥73.38 |
| Reason for the revision | No earnings forecast for the fiscal year ending March 2027 is provided because the company's shares are scheduled to be delisted following the tender offer by the tender offeror and the subsequent series of procedures. The reported results for the fiscal year ended March 2026 cite firm orders for blood pressure monitor cuffs, increased production volumes, a weaker yen against the U.S. dollar, and strong car-seat production at the Vietnam plant, among other factors. |
| Details and amount of extraordinary loss | Tender offer-related expenses ¥128.500 million, impairment loss ¥32.037 million, loss on disposal of fixed assets ¥0.995 million, total extraordinary losses ¥161.533 million |
| Dividend forecast revision | The year-end dividend for the fiscal year ended March 2026 is ¥0.00 (no dividend). The annual dividend forecast for the fiscal year ending March 2027 is also ¥0.00. The disclosure describes the revision to the dividend forecast to no dividend announced on 15 December 2025. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Medical Healthcare Business, orders for blood pressure monitor cuffs remained firm, production volumes increased, and the weaker yen against the U.S. dollar also contributed. In the Safety Systems Business, production volumes declined following the reduction from the large sales of sewing automation machines in the previous fiscal year and product changes for airbags. However, strong car-seat production at the Vietnam plant improved profitability. No earnings forecast for the fiscal year ending March 2027 is provided because the company is scheduled to be delisted following the tender offer and subsequent procedures.